Osteoporosis – Pipeline Review, H1 2017, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.
Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/289282 .
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Osteoporosis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 5, 5, 11, 57, 11 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 10 and 13 molecules, respectively.
Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Browse the full report @ http://www.orbisresearch.com/reports/index/osteoporosis-pipeline-review-h1-2017 .
– The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
– The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/289282 .
Addex Therapeutics Ltd
Alize Pharma SAS
Alvogen Korea Co Ltd
Amura Holdings Ltd
Bone Biologics Corp
Bristol-Myers Squibb Company
ChoDang Pharm Co Ltd
Chugai Pharmaceutical Co Ltd
Corium International Inc
Critical Pharmaceuticals Ltd
Daiichi Sankyo Company Ltd
Entera Bio Ltd
Enteris BioPharma Inc
Enzo Biochem Inc
F. Hoffmann-La Roche Ltd
GL Pharm Tech Corp
Glide Pharmaceutical Technologies Ltd
Hanmi Pharmaceuticals Co Ltd
Haoma Medica Ltd
Intas Pharmaceuticals Ltd
Kaken Pharmaceutical Co Ltd
Lead Discovery Center GmbH
Ligand Pharmaceuticals Inc
Lotus Pharmaceutical Co Ltd
Merck & Co Inc
Mereo Biopharma Group Plc
Osteologix Holdings Plc
Paras Biopharmaceuticals Finland Oy
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shin Poong PharmCo Ltd
Sinil Pharmaceutical Co Ltd
Stelis Biopharma Pvt Ltd
Sumitomo Dainippon Pharma Co Ltd
Terpenoid Therapeutics Inc
TSH Biopharm Corporation Ltd
Uni-Bio Science Group Ltd
Viking Therapeutics Inc
Wroclawskie Centrum Badan EIT+ Sp z oo
Yooyoung Pharm Co Ltd
Zydus Cadila Healthcare Ltd
For any enquires before buying, connect with us @ firstname.lastname@example.org
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For more information contact email@example.com